Kelley Lauren Coffman, MD, on the Next Steps for a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the next steps for a study which evaluated patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE.

Study findings presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that investigators saw a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, explained what she believes are the next steps for this research.

Transcription:

Our group has a particular interest in identifying genetic or biomarkers that might help beforehand to predict a patient’s response to therapy. Even in our study [and] in our review of these patients, we looked at the last 2 years. We had access to genetic sequencing, and about two-thirds of the tumors [by] a basic genetic review [demonstrated] mutations…similar to what we expected for well-differentiated tumor types. In the future, going forward, we’d really like to see if there’s a way to identify either genetic or biomarkers that might predict response or resistance to this therapy so that beforehand, you could really identify which patients are going to benefit without subjecting them to the toxicities.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content